Compare Galaxy Digital Inc. Class A Common Stock (GLXY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Galaxy Digital Inc. Class A Common Stock vs Tango Therapeutics Inc. — how do they compare? Galaxy Digital Inc. Class A Common Stock trades at $17.6 (market cap $3.83B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Galaxy Digital Inc. Class A Common Stock and Tango Therapeutics Inc. are close in size by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Galaxy Digital Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Galaxy Digital Inc. Class A Common Stock for 2 Days and Tango Therapeutics Inc. for 0 Days on average.
| GLXY | TNGX | |
|---|---|---|
Market Cap | $3.83B | $3.75B |
Volume | 5,859,599 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $42.86 | $32.90 |
52-Week Low | $16.84 | $7.50 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $6.28B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Galaxy Digital (GLXY) trades at $19.71, down 0.81% with bearish technical signals but strong analyst support. The company reported Q2 2026 EPS of -$0.09, beating expectations, though revenue declined to $57.4B in 2026 with a net loss of -$315M. Recent news includes a Citigroup upgrade to Buy and upcoming Q3 earnings on October 27, 2026.
Despite current losses, analyst consensus is bullish with an $38.20 price target (81.8% Buy ratings). Key risks include negative profit margins and cash flow challenges, but institutional buying and strategic partnerships provide upside potential if earnings improve.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Galaxy Digital Inc. Class A Common Stock
Galaxy provides digital-asset financial services and data center infrastructure. Its digital-assets business includes trading, asset management, investment banking, staking, tokenization, and custody technology.
Read more on GLXY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
